MR Imaging with Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea for Prostate Cancer
This study is looking at a special type of imaging called Magnetic Resonance (MR) Imaging using a substance called hyperpolarized 13C-pyruvate, sometimes with 13C,15N-urea, in men with prostate cancer. The goal is to see how well this imaging can show changes in prostate cancer cells, especially in those who are having or have had radiation therapy. Researchers want to find the best way to do these scans and measure how the cancer cells use energy. This information could help doctors understand how prostate cancer responds to treatment. The study plans to enroll 161 participants, and its current status is unclear.
- Study design
- This interventional study plans to enroll 161 men with prostate cancer. It is not specified if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- For some parts of the study, measurements will be taken for up to 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Robert Bok, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Signal-to-noise ratio (Part 1)Day of MR imaging (1 day)
A signal-to-noise ratio is defined as a MR/spectroscopy parameter, consisting of the HP C13-Pyruvate or Lactate signal (peak) relative to background noise level (baseline) in MRI spectra of the tissue.
- Mean HP 13C-pyruvate to lactate metabolic rate of conversion (kPL) over time (Part 2A)Up to 24 months
The mean percent change in tumoral kPL between baseline and 1-year post-EBRT will be reported.
- Mean HP 13C-pyruvate to glutamate metabolic rate of conversion (kPG) over time (Part 2A)Up to 24 months
The mean percent change in tumoral kPG between baseline and 1-year post-EBRT will be reported.
- Mean change in on-treatment kPL over time (Part 2B)Up to 24 months
Mean percent change in tumoral kPL for participants receiving systemic hormone therapy between baseline and 1 -year post-EBRT will be reported.
- Mean change in on-treatment kPG over time (Part 2B)Up to 24 months
Mean percent change in tumoral kPG for participants receiving systemic hormone therapy between baseline and 1 -year post-EBRT will be reported.
- Mean kPL at time of biochemical failure (Part 3)Up to 24 months
The mean kPL for participants with biochemical failure will be reported.
- Mean kPG at time of biochemical failure (Part 3)Up to 24 months
The mean kPG for participants with biochemical failure will be reported.